Title: Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with ATO
Abstract:OBJECTIVE:To study the incidence of leukocytosic and the retinoic acid syndrome (RAS) in newly diagnosed and relapsed acute promyelocytic leukemia (APL) patients treated with ATO. METHODS: Thirty pati...OBJECTIVE:To study the incidence of leukocytosic and the retinoic acid syndrome (RAS) in newly diagnosed and relapsed acute promyelocytic leukemia (APL) patients treated with ATO. METHODS: Thirty patients with newly diagnosed or relapsed APL were treated with ATO for remission induction at the dose of 10 mg/d. RESULTS: Twenty-three patients (77%) achieved complete remission. Mean time to remission was 37.1 days. Leukocytosis was observed in 14 patients(47%), mean time to leukocytosis was 12.9 days, median baseline leukocyte count for patients with leukocytosis was 3.1×109L -1, which was higher than that for patients who did not get leukocytosis (2.6×109L -1, z=-2.635, P=0.008). No other cytotoxic therapy was administered, and the leukocytosis resolved in all cases. The RA syndrome was observed in nine patients (30%), mean time to RA syndrome was 13.9 days, median baseline leukocyte count for patients with RA syndrome was 3.6×109L -1, which was higher than that for patients who did not get the RA syndrome (2.6×109L -1, z=-1.909, P=0.046). Patients who get leukocytosis were significantly more likely to worsen the RA syndrome, and no patient died of the RA syndrome. CONCLUSIONS: ATO is a safe and highly effective agent for inducing complete remissions in patients with newly diagnosed and relapsed APL. Leukocytosis and the RA syndrome are associated with ATO and with baseline leukocyte count, and there is distinct link between the two phenomena. Leukocytosis regresses with continued ATO treatment alone.Read More
Publication Year: 2006
Publication Date: 2006-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot